West Pharmaceutical Services Inc. (WST) reported a Q4 2023 adjusted EPS of $1.83, surpassing estimates but with sales slightly missing expectations. The company provided a cautious 2024 outlook, forecasting lower sales and EPS than consensus estimates, attributing this to moderated organic sales growth and inventory management challenges. Despite this, analysts at William Blair maintain an Outperform rating, emphasizing the need for West to clarify its position on destocking to reassure investors.